<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="449">
  <stage>Registered</stage>
  <submitdate>7/09/2005</submitdate>
  <approvaldate>21/10/2005</approvaldate>
  <actrnumber>ACTRN12605000683639</actrnumber>
  <trial_identification>
    <studytitle>Use of exhaled nitric oxide levels in predicting response to oral steroids in patients with COPD</studytitle>
    <scientifictitle>Use of exhaled nitric oxide levels in predicting response to oral steroids in patients with COPD</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic obstructive pulmonary disease (COPD)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Baseline exhaled nitric oxide levels are taken at the beginning of the study.  20mg Prednisone daily or placebo is given for 3 weeks in a cross-over design with a 4 week washout period.</interventions>
    <comparator>Placebo (sugar pill taken orally)</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>exercise capacity defined by 6 minute walk distance</outcome>
      <timepoint>Dec 08</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>exercise capacity defined by FEV1</outcome>
      <timepoint>Dec 08</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>St George Respiratory Questionnaire score.</outcome>
      <timepoint>Dec 08</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with COPDFEV1 &lt;70% predicted, FEV1/FVC ratio &lt;70%Smoker or ex-smoker of at least 20 pack years.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acute exacerbation within the last 3 months, patients receiving long-term oxygen treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelope</concealment>
    <sequence>Latin square design with blocking</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>3/01/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Health Research Council of New Zealand</primarysponsorname>
    <primarysponsoraddress>Health Research Council of New Zealand,
PO Box 5541,
Wellesley St,
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>Health Research Council of New Zealand, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago</sponsorname>
      <sponsoraddress>University of Otago, Dunedin</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor D Robin Taylor</name>
      <address>Otago Respiratory Research Group
Dunedin School of Medicine
University of Otago
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 (Ext. 8785)</phone>
      <fax />
      <email>robin.taylor@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jack Dummer</name>
      <address>Canterbury Respiratory Research Group, Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch.</address>
      <phone>+64 3 3640640 (Ext 89682)</phone>
      <fax />
      <email>jack.dummer@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>